PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer
Publication: ESMO Breast, Presentation ID: 65P Authors: Elena Shagisultanova, V. Borges, R. Layeequr Rahman, E. Brown, L. Gold, L. Matt-Amaral, L. Samiian, C.Godellas, B.A. Lesnikoski, G. Srkalovic, A. Shah, C. Collins, T. Bah, S. Uygun, N. Stivers, A. Menicucci, W. Audeh, J. A. O'Shaughnessy Title: Prognostic Performance of MammaPrint Read More
Genomically Basal-Type tumors demonstrate distinct immune profiles and chemosensitivity across self-reported race among patients enrolled in FLEX receiving neoadjuvant chemotherapy
Publication: ASBrS 2026, Abstract Number: 1062 Authors:Nathalie Johnson, Mehran Habibi, Marcela Mazo, Ahmed Elkhanany, Fengting Yan, Nicole Sookhan, J. Jaime Alberty-Oller, Laila Samiian, Eric Brown, Linsey Gold, Alfredo Santillan, Eduardo Dias, Sasha Davis, Laura Lee, Constantine Godellas, Abigail Beard, Gordan Srkalovic, Beth-Ann Lesnikoski, Sahra Uygun, Christina Page, Nicole Stivers, Read More
Prognostic Value of MammaPrint in Diverse Populations: Evaluating Racial Disparities in Breast Cancer Outcomes
Publication: JCO Precis Oncol. 2026 Apr;10(4):e2500926. doi: 10.1200/PO-25-00926. Epub 2026 Apr 9. Authors: Reine Abou Zeidane, Samuel Lichtman-Mikol, Courtney Pisano, Benjamin Hauk, Yilun Sun, Priyanka S Rana, Citlally Lopez-Flores, Breanna N McBean, Kassidy M Jungles, Trisha Lal, Nihit Mehta, Philip Bomeisl, Amanda L Amin, Alberto J Montero, Siran Koroukian, Read More
Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer
Publication: npj Breast Cancer, Article number: (2026) Authors: Sonya Reid; Lindsay Venton; Jennifer G. Whisenant; Anne E. Weidner; Jennifer Wei; Harshini Ramaswamy; Christa Dreezen; Nicole Chmielewski-Stivers;Andrea R. Menicucci; William Audeh; Tuya Pal Title: Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2– breast cancer Abstract: We compared Read More
Impact of Neoadjuvant Endocrine Therapy on MammaPrint Index in Hormone Receptor–Positive, HER2-Negative MammaPrint Low Risk Early-Stage Breast Cancer
Publication: SABCS 2025 Authors: Saya Jacob, Cynthia Wu, Annuska Glas, Christina Yau, Lamorna Brown-Swigart, Gillian Hirst, Tufia Haddad, Karthik Giridhar, Anthony Elias, Rita Mukhtar, Laura Huppert, Kathy Albain, Doug Yee, Laura van’t Veer, Laura Esserman2, Jo Chien Title: Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients Read More
FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer
Publication: SABCS 2025, Presentation ID: PS5-09-19 Authors: Gold et al. Title: FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer Introduction: Treatment approaches for early-stage breast cancer (EBC) have advanced significantly in recent decades, with the addition of HER2-targeted therapies, immunotherapy, and personalized chemotherapy. Read More
Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients With Obesity Enrolled in FLEX
Publication: SABCS 2025, Presentation ID: PS4-09-09 Authors: Mazo Canola et al. Title: Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients With Obesity Enrolled in FLEX Introduction: Latin American (LA) women are more often diagnosed with aggressive early breast cancer (EBC) than Non-Hispanic White (NHW) women1. Prior Read More